Dimerix gains on ethics approval for COVID-19 study in Australia
23/12/2021 02:53
** Shares of Dimerix Ltd DXB.AX rise as much as 4.4% to
A$0.24, marking their biggest intraday pct gain since Dec. 13
** Pharmaceutical co receives https://www.asx.com.au/asxpdf/20211223/pdf/454hcnqc25xfrd.pdf
ethics approval for phase 3 clinical trial of DMX-200 in
COVID-19 patients in Australia
** Co will start recruiting and dosing patients across NSW,
Victoria and Queensland in January
** In Sept, co had received approval for the study in India
urn:newsml:reuters.com:*:nL4N2QQ04N
** Stock hits its highest since Dec. 14
** Stock down 2.1% this year, as of last close
(Reporting by Dhriti Garg in Bengaluru)
((dhriti.garg@thomsonreuters.com))
Recent news on Dimerix
See all newsAustralia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region
Brief: Everest Medicine In Agreement With Dimerix To Develop Commercialize DMX-200 In Greater China, South Korea, And Southeast Asia
Brief: Dimerix Seeks Trading Halt
Brief: Dimerix To Conduct Review Of Action3 Statistical Assumptions